Cargando…
Response adaptive designs for Phase II trials with binary endpoint based on context-dependent information measures()
In many rare disease Phase II clinical trials, two objectives are of interest to an investigator: maximising the statistical power and maximising the number of patients responding to the treatment. These two objectives are competing, therefore, clinical trial designs offering a balance between them...
Autores principales: | Kasianova, Ksenia, Kelbert, Mark, Mozgunov, Pavel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985674/ https://www.ncbi.nlm.nih.gov/pubmed/34083846 http://dx.doi.org/10.1016/j.csda.2021.107187 |
Ejemplares similares
-
A flexible design for advanced Phase I/II clinical trials with continuous efficacy endpoints
por: Mozgunov, Pavel, et al.
Publicado: (2019) -
An information theoretic phase I–II design for molecularly targeted agents that does not require an assumption of monotonicity
por: Mozgunov, Pavel, et al.
Publicado: (2018) -
An adaptive seamless phase II/III clinical trial design incorporating short-term endpoint information
por: Stallard, Nigel
Publicado: (2011) -
Practical recommendations for implementing a Bayesian adaptive phase I design during a pandemic
por: Ewings, Sean, et al.
Publicado: (2022) -
Using short-term endpoints to improve interim decision making and trial duration in two-stage phase II trials with nested binary endpoints
por: Zocholl, Dario, et al.
Publicado: (2023)